Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 1, Pages 228
Publisher
MDPI AG
Online
2019-01-09
DOI
10.3390/ijms20010228
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1 -Mutated AML
- (2018) Yi Zhou et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation
- (2018) Christina Rautenberg et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
- (2018) Marcos de Lima et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2018) Ibrahim Aldoss et al. HAEMATOLOGICA
- Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
- (2018) Kiyomi Morita et al. JOURNAL OF CLINICAL ONCOLOGY
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
- (2018) Hardikkumar Jetani et al. LEUKEMIA
- Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
- (2018) Maja Rothenberg-Thurley et al. LEUKEMIA
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
- (2018) Nimitha R Mathew et al. NATURE MEDICINE
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia
- (2018) David P. Steensma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Minimal Residual Disease in Acute Myeloid Leukemia
- (2018) Mojca Jongen-Lavrencic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Donor lymphocyte infusion in myeloid disorders
- (2018) Selami Koçak Toprak TRANSFUSION AND APHERESIS SCIENCE
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2018) Ibrahim Aldoss et al. HAEMATOLOGICA
- Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2
- (2018) Amir T. Fathi et al. JAMA Oncology
- Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
- (2018) Felicitas Thol et al. BLOOD
- Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- (2018) Catherine J. Lee et al. BONE MARROW TRANSPLANTATION
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial
- (2018) Juliette Lambert et al. HAEMATOLOGICA
- Acute myeloid leukaemia
- (2018) Nicholas J Short et al. LANCET
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT
- (2018) Christoph Schmid et al. BRITISH JOURNAL OF HAEMATOLOGY
- SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML
- (2018) Courtney D. DiNardo et al. Clinical Lymphoma Myeloma & Leukemia
- Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives
- (2018) Fabio Forghieri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation
- (2018) Mareike Frick et al. JOURNAL OF CLINICAL ONCOLOGY
- Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
- (2018) Uwe Platzbecker et al. LANCET ONCOLOGY
- Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT
- (2017) Christina Rautenberg et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect
- (2017) Guillermo Orti et al. EXPERIMENTAL HEMATOLOGY
- Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation
- (2017) Christoph Schmid et al. HAEMATOLOGICA
- Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
- (2017) Pierre Hirsch et al. HAEMATOLOGICA
- Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation
- (2017) Thomas Schroeder et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
- (2017) Lars Bullinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
- (2017) Mingxue Fan et al. Journal of Hematology & Oncology
- Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression
- (2017) Melanie T. Rebechi et al. LEUKEMIA & LYMPHOMA
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
- (2017) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations
- (2017) Anne-Kathrin Garz et al. Oncotarget
- Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation
- (2017) Christoph Schmid et al. HAEMATOLOGICA
- Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
- (2017) Pierre Hirsch et al. HAEMATOLOGICA
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
- (2016) P Tsirigotis et al. BONE MARROW TRANSPLANTATION
- Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing
- (2016) Erik B.R. Malmberg et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Assessment of Minimal Residual Disease in Standard-Risk AML
- (2016) Adam Ivey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
- (2015) Thomas Schroeder et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study
- (2015) Nelli Bejanyan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
- (2015) Iskra Pusic et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Minimal residual disease-directed therapy in acute myeloid leukemia
- (2015) S. Kayser et al. BLOOD
- Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
- (2015) D. Grimwade et al. BLOOD
- Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation
- (2015) Z Jedlickova et al. BONE MARROW TRANSPLANTATION
- Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation
- (2015) Tanja Stahl et al. EXPERIMENTAL HEMATOLOGY
- Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
- (2015) C. Willekens et al. HAEMATOLOGICA
- Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
- (2015) Jeffery M. Klco et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome
- (2015) Seunghoon Han et al. Journal of Hematology & Oncology
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
- (2015) C. Willekens et al. HAEMATOLOGICA
- Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
- (2014) R. F. Schlenk et al. BLOOD
- Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
- (2014) D. Grimwade et al. BLOOD
- In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification
- (2014) Y. Wang et al. BLOOD
- Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation
- (2014) J Tischer et al. BONE MARROW TRANSPLANTATION
- Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia
- (2014) Gaku Oshikawa et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation
- (2014) Mariana Bastos-Oreiro et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation
- (2014) L Crucitti et al. LEUKEMIA
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity
- (2013) Xiao-su Zhao et al. ANNALS OF HEMATOLOGY
- Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation
- (2013) Marcos de Lima et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
- (2013) A. Galanis et al. BLOOD
- The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML
- (2013) N. Shayegi et al. BLOOD
- Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
- (2013) J. Kronke et al. BLOOD
- Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
- (2013) E. Jourdan et al. BLOOD
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
- (2013) F. Ravandi et al. BLOOD
- Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change
- (2013) Maximilian Christopeit et al. JOURNAL OF CLINICAL ONCOLOGY
- Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation
- (2013) T Schroeder et al. LEUKEMIA
- Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
- (2013) T Schroeder et al. LEUKEMIA
- Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia
- (2013) Giovanni Rossi et al. LEUKEMIA & LYMPHOMA
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Minimal Residual Disease by Real-Time Quantitative PCR of Wilms’ Tumor 1 Expression in Patients with Acute Myelogenous Leukemia after Allogeneic Stem Cell Transplantation: Correlation with Flow Cytometry and Chimerism
- (2012) Mi Kwon et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with an Alemtuzumab-Containing Conditioning Regimen
- (2012) Maria Liga et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT
- (2012) C. Toffalori et al. BLOOD
- Azacitidine after allo-SCT: the good without the bad?
- (2012) M. Mohty et al. BLOOD
- Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
- (2012) O. C. Goodyear et al. BLOOD
- Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
- (2012) J. A. L. Yin et al. BLOOD
- Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study
- (2012) Yu Wang et al. CLINICAL TRANSPLANTATION
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
- (2012) S K Metzelder et al. LEUKEMIA
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia
- (2011) Djordje Atanackovic et al. AMERICAN JOURNAL OF HEMATOLOGY
- Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
- (2011) C. Schmid et al. BLOOD
- Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse
- (2011) K. Sockel et al. HAEMATOLOGICA
- Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
- (2011) Jan Krönke et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
- (2011) U Platzbecker et al. LEUKEMIA
- Sorafenib Treatment in 13 Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations in Combination with Chemotherapy or as Monotherapy
- (2010) Thomas Schroeder et al. ACTA HAEMATOLOGICA
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse Following Allogeneic Stem Cell Transplantation. Part II: Chronic Leukemias, Myeloproliferative Neoplasms, and Lymphoid Malignancies
- (2010) Nicolaus Kröger et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
- (2010) Marcos de Lima et al. CANCER
- Prognostic Impact of Minimal Residual Disease inCBFB-MYH11–Positive Acute Myeloid Leukemia
- (2010) Andrea Corbacioglu et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning
- (2010) T Lange et al. LEUKEMIA
- Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
- (2010) Ted A. Gooley et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNMT3AMutations in Acute Myeloid Leukemia
- (2010) Timothy J. Ley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
- (2009) S. Schnittger et al. BLOOD
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation
- (2009) M. Bornhauser et al. HAEMATOLOGICA
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission
- (2009) John Koreth et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
- (2009) Daniela Cilloni et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation
- (2009) Luca Vago et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
- (2009) Elaine R. Mardis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantitative assessment ofWT1gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia
- (2008) Anna Candoni et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Sorafenib (Nexavar®) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia
- (2008) N.N. Safaian et al. LEUKEMIA RESEARCH
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
- (2008) Richard F. Schlenk et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now